Aldevron News: Protein

In the News: Isolere Bio Enters into Agreement with Aldevron to Develop a Scalable Manufacturing Process for IsoTag Reagents

Isolere  Bio, a biotech firm working to develop a low-cost, high throughput, and scalable purification platform, has entered into an agreement with Aldevron , a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, to develop a low-cost manufacturing strategy for its IsoTag™ reagents, that is able to easily scale up to meet demand for an industry that is seeing tremendous growth and bottleneck pressures.
Read More

In the News: Aldevron Expands Manufacturing Capabilities in Madison

On February 10, Aldevron hosted a virtual celebration of its lab facility expansion in Madison.
 
Aldevron produces the raw materials that allow clients to make groundbreaking therapies, and its protein business unit has operated within University Research Park since 2009. The facility’s growth from 8,000 to nearly 30,000 square feet includes a new 3,500-square-foot fermentation suite and will allow the company to expand its projects’ scope and scale.
 
Read the full article from University of Wisconsin-Madison   here.
 
Additionally, Tom Foti, President of Aldevron's Protein Business Unit provided a virtual tour, which you can view below!
Read More

Advancing Direct Enzyme Delivery for Therapeutic Genome Editing In Vivo

Genome editing enzymes such as Cas9 have been successfully employed to target different genetic disorders in model systems, and ex vivo approaches have demonstrated the clinical potential of this technology. However, the challenge of delivering such corrective enzymes in vivo represents a substantial barrier to therapeutic translation.  

Viral vectors—refined during their use in traditional gene therapy—represent the most widely-used delivery platform in preclinical work, and nanoparticles are quickly maturing into a comparably powerful vehicle. Direct delivery of pre-formed CRISPR enzymes has recently emerged as an appealing strategy for enabling therapeutic editing in vivo.  

Read More

Aldevron Releases GMP-Grade SpyFi™ Cas9 Nuclease

Product is the result of a partnership with Integrated DNA Technologies, Inc., and provides clinical stage clients with a critical raw material 

Aldevron is announcing the release of GMP SpyFi Cas9 Nuclease for clinical and commercial applications. SpyFi Cas9 Nuclease, the trade name for Aldevron’s research grade and GMP products, is the direct result of a partnership with Integrated DNA Technologies, Inc. (IDT). The advantages of SpyFi Cas9 Nuclease include reduced off-target effects combined with clinically relevant on-target activity.

Read More

Aldevron to Provide New GMP Cas9 Nuclease Through Agreement with Integrated DNA Technologies

Aldevron and Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFiTM Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.  

Read More

Aldevron Announces Availability of GMP SpCas9

Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services, announces the availability of GMP-grade SpCas9 nuclease for use in clinical development programs.  Aldevron’s GMP SpCas9 is designed to accelerate gene editing clinical trials and commercial applications by providing an immediate enzyme supply; thereby eliminating months typically associated with contract GMP production and testing.

Read More